Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS currently manages 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct examiners, showing a high degree of individual oversight. This ratio between actions and examiners suggests that no single individual has a dominant influence over the portfolio. Such a distribution allows for a broader range of examiner feedback on the company's pharmaceutical research.
DANIEL JOHN BURKETT is the busiest examiner for the portfolio, with 1 pending office action. The prosecution is also spread across distinct art units, meaning each matter is reviewed in a unique departmental setting. For the organization, this means that prosecution strategies must be tailored to different examiner preferences to resolve the 5 pending office actions. This decentralized approach requires a versatile legal strategy to navigate the various requirements of the assigned examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 1 | 63.4% | +33.2% |
| WOOLWINE, SAMUEL C | 1 | 61.0% | +20.3% |
| LI, BAO Q | 1 | 75.5% | +26.7% |
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| MCCORMACK, ERIN KATHLEEN | 1 | 7.9% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17790029 | PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW | MCCORMACK, ERIN KATHLEEN | 15d overdue |
| 18862189 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM | BURKETT, DANIEL JOHN | — |
| 18723155 | DETECTION OF TELOMERE FUSION EVENTS | WOOLWINE, SAMUEL C | — |
| 18553464 | ANTIBODY AND USE THEREOF FOR THE TREATMENT OF CANCER | GODDARD, LAURA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17790029 | PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW | MCCORMACK, ERIN KATHLEEN | 15d overdue |
| 18862189 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM | BURKETT, DANIEL JOHN | — |
| 18723155 | DETECTION OF TELOMERE FUSION EVENTS | WOOLWINE, SAMUEL C | — |
| 18713083 | CORONAVIRUS DERIVED RNA REPLICONS AND THEIR USE AS VACCINES | LI, BAO Q | — |
| 18553464 | ANTIBODY AND USE THEREOF FOR THE TREATMENT OF CANCER | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1681 | 1 |
| 1671 | 1 |
| 1642 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18862189 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM | BURKETT, DANIEL JOHN | 1624 | §102§112 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18723155 | DETECTION OF TELOMERE FUSION EVENTS | WOOLWINE, SAMUEL C | 1681 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18713083 | CORONAVIRUS DERIVED RNA REPLICONS AND THEIR USE AS VACCINES | LI, BAO Q | 1671 | §112 | Non-Final OA | — | Pending | May 23, 2024 |
| 18553464 | ANTIBODY AND USE THEREOF FOR THE TREATMENT OF CANCER | GODDARD, LAURA B | 1642 | §101§102 | Final Rejection | — | Pending | Sep 29, 2023 |
| 17790029 | PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW | MCCORMACK, ERIN KATHLEEN | 3791 | §103 | Final Rejection | 15d overdue | Pending | Jun 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Daniel John Burkett has the most, with 1 of CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
